Ixabepilone

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: HR+/HER2- Metastatic Breast Cancer, Breast Cancer

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (7)
Breast Cancer
NCT00789581 · SCRI Development Innovations, LLC
2008-12 – 2016-11 · Breast Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT00630032 · UNICANCER
2007-09 – 2020-09-03 · Breast Cancer
What this study did
NCT00785291 · National Cancer Institute (NCI)
2008-10-13 – 2017-06-15 · Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, HER2/Neu Positive, Progesterone Receptor Negative, Progesterone Receptor Positive, Recurrent Breast Carcinoma, Stage IIIC Breast Cancer AJCC v6, Stage IV Breast Cancer AJCC v6 and v7
What this study did
NCT00998738 · Mayo Clinic
2009-11 – 2013-01 · Neuropathy, Pain, Recurrent Breast Carcinoma, Stage IV Breast Cancer
What this study did
Other / comorbidity
NCT00883116 · R-Pharm
2009-08 – 2014-02 · Endometrial Cancer
What this study did
Phase 2 (58)
Breast Cancer
NCT00821886 · SCRI Development Innovations, LLC
2009-02 – 2014-10 · Breast Cancer
What this study did
NCT00866905 · SCRI Development Innovations, LLC
2009-04 – 2014-10 · Breast Cancer
What this study did
NCT00751868 · Consorzio Oncotech
2008-09 – 2011-07 · Breast Cancer
What this study did
NCT00633464 · R-Pharm
2008-06 – 2011-05 · Triple Negative Locally Advanced Non-resectable Breast Cancer, Metastatic Breast Cancer
What this study did
NCT00079326 · National Cancer Institute (NCI)
2004-01 – 2010-10 · HER2-positive Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT00877500 · M.D. Anderson Cancer Center
2009-03-30 – 2026-12-31 · Bilateral Breast Carcinoma, HER2/Neu Negative, Invasive Breast Carcinoma
What this study did
NCT04796324 · Allarity Therapeutics
2021-03-01 – 2025-11-01 · Metastatic Breast Cancer
What this study did
NCT01446016 · The Methodist Hospital Research Institute
2011-09 – 2019-03-01 · Breast Neoplasms, Breast Cancer
What this study did
NCT01818999 · University of Texas Southwestern Medical Center
2013-08 – 2015-04 · METASTATIC BREAST CANCER
What this study did
NCT00879086 · Eisai Inc.
2009-03-31 – 2014-04-30 · Breast Cancer
What this study did
NCT01075100 · US Oncology Research
2010-01 – 2013-06 · Metastatic Breast Cancer
What this study did
NCT00490646 · R-Pharm
2008-02 – 2011-11 · Metastatic Breast Cancer
What this study did
NCT00790894 · Hellenic Cooperative Oncology Group
2008-11 – 2011-05 · Metastatic Breast Cancer
What this study did
NCT00077376 · National Cancer Institute (NCI)
2005-03 – 2011-03 · HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
What this study did
NCT00627978 · Weill Medical College of Cornell University
2007-11 – 2011-01 · Metastatic Breast Cancer
What this study did
NCT00593827 · R-Pharm
2008-05 – 2010-08 · Metastatic Breast Cancer
What this study did
NCT00546364 · R-Pharm
2008-02 – 2010-03 · Breast Neoplasms
What this study did
NCT00370552 · R-Pharm
2007-03 – 2009-11 · Metastatic Breast Cancer
What this study did
NCT00045097 · National Cancer Institute (NCI)
2002-05 – 2007-07 · Breast Cancer
What this study did
NCT01027208 · R-Pharm
2006-12 – 2007-01 · Metastatic Breast Cancer
What this study did
NCT00080262 · R-Pharm
2004-02 – 2006-12 · Breast Cancer, Metastases
What this study did
NCT00020904 · Memorial Sloan Kettering Cancer Center
2001-02 – 2003-01 · Breast Cancer
What this study did
Other / comorbidity
NCT00977574 · National Cancer Institute (NCI)
2009-09-14 – 2027-03-06 · Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Recurrent Malignant Uterine Corpus Neoplasm, Stage IIIA Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage, Stage IIIB Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage, Stage IIIC Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage, Stage IVA Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage, Stage IVB Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage
What this study did
NCT00828308 · Brown University
2009-02 – 2016-12 · Prostate Cancer
What this study did
NCT00923130 · National Cancer Institute (NCI)
2009-01-07 – 2016-06 · Renal Cell Carcinoma
What this study did
NCT01220609 · National Cancer Institute (NCI)
2010-11 – 2016-01 · Recurrent Uterine Corpus Sarcoma, Uterine Corpus Leiomyosarcoma
What this study did
NCT01057212 · Providence Health & Services
2010-02 – 2013-12 · Non-squamous Non-small Cell Lung Cancer
What this study did
NCT00924066 · National Cancer Institute (NCI)
2008-11 – 2013-12 · Cervical Carcinoma, Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Carcinoma, Non-SquamousType
What this study did
NCT01168232 · National Cancer Institute (NCI)
2010-09-07 – 2013-11-26 · Recurrent Uterine Corpus Sarcoma, Uterine Carcinosarcoma
What this study did
NCT00741988 · SCRI Development Innovations, LLC
2008-09 – 2012-09 · Non-Small Cell Lung Cancer
What this study did
NCT00672009 · Cedars-Sinai Medical Center
2008-04 – 2012-08 · Prostatic Diseases, Genital Neoplasms, Male, Urogenital Neoplasms, Genital Diseases, Male, Adenocarcinoma, Prostatic Neoplasms, Neoplasms, Glandular and Epithelial, Carcinoma
What this study did
NCT00030992 · National Cancer Institute (NCI)
2002-02 – 2012-06 · Renal Cell Carcinoma
What this study did
NCT00723957 · R-Pharm
2008-12 – 2011-08 · Advanced/Metastatic Non-Small Cell Lung Cancer
What this study did
NCT00983801 · R-Pharm
2009-11 – 2011-06 · Stomach Neoplasms
What this study did
NCT00087139 · National Cancer Institute (NCI)
2004-09 – 2011-02 · Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer
What this study did
NCT00058019 · National Cancer Institute (NCI)
2003-02 – 2010-08 · Anaplastic Large Cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma
What this study did
NCT00025155 · National Cancer Institute (NCI)
2002-07 – 2010-03 · Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer
What this study did
NCT00998101 · UNC Lineberger Comprehensive Cancer Center
2009-07 – 2009-11 · Lung Cancer
What this study did
NCT00023946 · National Cancer Institute (NCI)
2001-08 – 2009-11 · Adult Primary Cholangiocellular Carcinoma, Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Cholangiocarcinoma of the Extrahepatic Bile Duct, Cholangiocarcinoma of the Gallbladder, Localized Extrahepatic Bile Duct Cancer, Localized Gallbladder Cancer, Localized Resectable Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer, Recurrent Extrahepatic Bile Duct Cancer, Recurrent Gallbladder Cancer, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer
What this study did
NCT00095979 · National Cancer Institute (NCI)
2005-05 – 2009-07 · Endometrial Adenocarcinoma, Recurrent Endometrial Carcinoma, Stage IV Endometrial Carcinoma
What this study did
NCT00331643 · National Cancer Institute (NCI)
2006-04 – 2009-06 · Adult Rhabdomyosarcoma, Adult Synovial Sarcoma, Alveolar Childhood Rhabdomyosarcoma, Childhood Synovial Sarcoma, Embryonal Childhood Rhabdomyosarcoma, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Recurrent Wilms Tumor and Other Childhood Kidney Tumors
What this study did
NCT00383149 · R-Pharm
2007-01 – 2009-06 · Metastatic Pancreatic Cancer
What this study did
NCT00058084 · National Cancer Institute (NCI)
2003-03 – 2007-10-01 · Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer
What this study did
NCT00182702 · National Cancer Institute (NCI)
2005-07 – 2007-09 · Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer
What this study did
NCT00021099 · National Cancer Institute (NCI)
2001-06 – 2007-08 · Distal Urethral Cancer, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Proximal Urethral Cancer, Recurrent Bladder Cancer, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Urethral Cancer, Regional Transitional Cell Cancer of the Renal Pelvis and Ureter, Stage III Bladder Cancer, Stage IV Bladder Cancer, Transitional Cell Carcinoma of the Bladder, Urethral Cancer Associated With Invasive Bladder Cancer
What this study did
NCT00052572 · Memorial Sloan Kettering Cancer Center
2002-10 – 2007-07 · Leukemia, Lymphoma
What this study did
NCT00070096 · Memorial Sloan Kettering Cancer Center
2003-08 – 2007-06 · Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor, Ovarian Cancer, Testicular Germ Cell Tumor
What this study did
NCT00030706 · Montefiore Medical Center
2004-11 – 2007-02 · Ovarian Cancer, Peritoneal Cavity Cancer
What this study did
Phase 1/2 (11)
HR+/HER2- Metastatic Breast Cancer
NCT01349088 · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
2013-12 – 2018-09 · Breast Cancer, Metastatic Breast Cancer, Stage IV Breast Cancer
What this study did
NCT00825734 · SCRI Development Innovations, LLC
2009-03 – 2014-08 · Metastatic Breast Cancer
What this study did
NCT00182767 · National Cancer Institute (NCI)
2006-01 – 2014-05 · Fallopian Tube Cancer, Female Reproductive Cancer, Recurrent Breast Cancer, Recurrent Ovarian Epithelial Cancer, Stage III Ovarian Epithelial Cancer, Stage IV Breast Cancer, Stage IV Ovarian Epithelial Cancer
What this study did
NCT00924352 · Accelerated Community Oncology Research Network
2009-06 – 2013-10 · Metastatic Breast Cancer
What this study did
NCT00765765 · University of Medicine and Dentistry of New Jersey
2009-02 – 2011-12 · Breast Cancer
What this study did
Other / comorbidity
NCT01079793 · University of Texas Southwestern Medical Center
2010-05-26 – 2011-10-17 · Prostate Cancer
What this study did
NCT00331344 · National Cancer Institute (NCI)
2006-04 – 2010-11 · Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer
What this study did
NCT00045708 · National Cancer Institute (NCI)
2002-10 – 2010-05 · Adult Anaplastic Astrocytoma, Adult Giant Cell Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
What this study did
NCT00309049 · R-Pharm
2006-04 – 2007-05 · Cancer
What this study did
NCT00025194 · Memorial Sloan Kettering Cancer Center
2001-07 – 2006-07 · Prostate Cancer
What this study did
NCT00057850 · National Cancer Institute (NCI)
2002-01 – 2003-07 · Head and Neck Cancer
What this study did
Phase 1 (30)
HR+/HER2- Metastatic Breast Cancer
NCT01084057 · City of Hope Medical Center
2010-06-02 – 2019-09-27 · Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
What this study did
NCT00049244 · R-Pharm
started 2002-09 · Breast Cancer
What this study did
NCT00637897 · Wake Forest University Health Sciences
2008-03 – 2013-03 · Breast Cancer
What this study did
NCT01012362 · Masonic Cancer Center, University of Minnesota
2009-12 – 2013-02 · Breast Cancer, Lung Cancer, Colon Cancer, Pancreatic Cancer, Head and Neck Cancer, Kidney Cancer, Sarcoma, Hepatocellular Cancer
What this study did
NCT00634088 · R-Pharm
2008-06 – 2010-06 · Locally Advanced or Metastatic Breast Cancer
What this study did
NCT00568022 · R-Pharm
2008-02 – 2010-01 · Breast Cancer
What this study did
NCT00322374 · R-Pharm
2006-08 – 2009-02 · Metastatic Breast Cancer
What this study did
Other / comorbidity
NCT01375829 · National Cancer Institute (NCI)
2011-06-27 – 2027-03-19 · Adult Solid Neoplasm
What this study did
NCT00884676 · Jaime Merchan
2008-11 – 2015-07 · Unspecified Adult Solid Tumor, Protocol Specific
What this study did
NCT00798252 · Bristol-Myers Squibb
2009-03 – 2015-05 · Advanced Cancer
What this study did
NCT01170871 · University of Southern California
— · Advanced Solid Tumors
What this study did
NCT00804310 · University of California, Davis
2009-08 – 2011-09 · Unspecified Adult Solid Tumor, Protocol Specific
What this study did
NCT00717704 · Medstar Health Research Institute
2008-07 – 2011-05 · Solid Tumor
What this study did
NCT00422097 · R-Pharm
2007-01 – 2011-04 · Cancer
What this study did
NCT00832117 · R-Pharm
2009-05 – 2011-01 · Non Small Cell Lung Cancer
What this study did
NCT00030108 · National Institutes of Health Clinical Center (CC)
2001-11 – 2010-04 · Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer, Leukemia, Liver Cancer, Neuroblastoma, Ovarian Cancer, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
What this study did
NCT00683904 · R-Pharm
2008-06 – 2009-09 · Non-small Cell Lung Cancer (NSCLC)
What this study did
NCT00632424 · R-Pharm
2008-05 – 2009-06 · Advanced Solid Tumors
What this study did
NCT00207090 · R-Pharm
2005-09 – 2008-11 · Advanced Solid Tumors, Neoplasms
What this study did
NCT00043095 · Memorial Sloan Kettering Cancer Center
started 2002-06 · Unspecified Adult Solid Tumor, Protocol Specific
What this study did
NCT00162136 · R-Pharm
2005-09 – 2008-07 · Solid Malignancies
What this study did
NCT00049400 · SWOG Cancer Research Network
2003-10 – 2007-12 · Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
What this study did
NCT00362830 · Bristol-Myers Squibb
2006-08 – 2007-09 · Cancer
What this study did
NCT00028561 · National Cancer Institute (NCI)
2001-10 – 2007-02 · Unspecified Adult Solid Tumor, Protocol Specific
What this study did
NCT00096317 · Montefiore Medical Center
2003-03 – 2005-12-05 · Unspecified Adult Solid Tumor, Protocol Specific
What this study did
NCT00006221 · National Cancer Institute (NCI)
2000-11 – 2005-06 · Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
What this study did
NCT01018966 · R-Pharm
2004-04 – 2005-04 · Solid Tumors
What this study did
NCT00004927 · R-Pharm
1999-07 – 2002-10 · Unspecified Adult Solid Tumor, Protocol Specific
What this study did
Used as active comparator (2)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (1)
Phase 2 (1)
HR+/HER2- Metastatic Breast Cancer
NCT01416389 · Eli Lilly and Company
2011-08 – 2013-09 · Metastatic Breast Cancer
What this study did
Appears in other studies (2)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 2 (2)
Breast Cancer
NCT01097642 · The Methodist Hospital Research Institute
2008-10-10 – 2019-12 · Breast Cancer
What this study did
Other / comorbidity
NCT03093155 · Yale University
2017-04-03 – 2022-12-29 · Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
What this study did

Competitive landscape

3 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Breast Cancer: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Ixabepilone: this drugApprovedSmall moleculeMicrotubules (tubulin)Partial signalFeatured results are non-efficacy only in this race
Abemaciclib (Verzenio)ApprovedSmall moleculeCDK4 and CDK6Reliable signal
NCT02107703: Progression-Free Survival (PFS) (From Date of Randomization until Disease Progression or Death Due to Any Cause (Up To 31 Months)): Abemaciclib + Fulvestrant 16.4 Months (95% CI 14.4 to 19.3) vs Placebo + Fulvestrant 9.3 Months (95% CI 7.4 to 11.4)
NCT02102490: Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR]) (From Date of First Dose until Disease Progression or Death Due to Any Cause (Up To 14 Months)): Abemaciclib 19.7% (95% CI 13.3 to 27.5)
Alpelisib (BYL719)ApprovedSmall moleculePI3K-alphaReliable signal
NCT02437318: Progression-free Survival (PFS) Per Investigator Assessment in the PIK3CA Mutant Cohort (Once approximately 243 PFS events in the PIK3CA mutant cohort had been observed, up to 33.3 months): PIK3CA Mutant Cohort by Tumor Tissue: Alpelisib + Fulvestrant 11 Months (95% CI 7.49 to 14.52) vs PIK3CA Mutant Cohort by Tumor Tissue: Placebo + Fulvestrant 5.7 Months (95% CI 3.65 to 7.36)
Camizestrant (Etcamah)ApprovedSmall moleculeEstrogen receptorReliable signal
NCT04964934: SERENA-6 (NCT04964934), primary endpoint PFS: median PFS 16.0 months (camizestrant + CDK4/6i) vs 9.2 months (aromatase inhibitor + CDK4/6i); HR 0.44 (95% CI 0.31-0.60); p<0.00001
NCT04588298: Percentage Change From Baseline in Estrogen Receptor (ER) Expression Between Pre- and On-treatment Tumour Samples (Primary Analysis) (Baseline (Screening Day -21 to 1) to Biopsy day (Days 5-7 [Stage 1 and 2] or Days 12-15 [Stage 3])): AZD9833 75 mg (Stage 1 + 2) -62.7% (95% CI -67.46--57.93) vs AZD9833 150 mg (Stage 1 + 2) -62.8% (95% CI -67.13--58.43) vs AZD9833 300 mg (Stage 2) -67.1% (95% CI -74.49--59.74) vs AZD9833 75 mg (Stage 3) -66.9% (95% CI -72.34--61.46) vs AZD9833 150 mg (Stage 3) -65.0% (95% CI -70.27--59.81)
CapivasertibApprovedSmall moleculeAKT (inhibitor)Reliable signal
NCT04305496: Progression Free Survival: Overall Population (Months) in the Global Cohort (Assessed every 8 weeks for the first 18 months and every 12 weeks thereafter, from randomization to radiological progression.): Capivasertib + Fulvestrant (Global + China Cohort) 7.2 Months (95% CI 5.5 to 7.4) vs Placebo + Fulvestrant (Global + China Cohort) 3.6 Months (95% CI 2.8 to 3.7)
NCT01625286: Progression-free survival, Part B (randomized vs placebo + paclitaxel): median 10.9 months (95% CI 8.3 to 12.4) with capivasertib vs 8.4 months (95% CI 8.2 to 10.8) with placebo; HR 0.80 (95% CI 0.60 to 1.06), p=0.308 (CT.gov posted results). missed
Datopotamab DeruxtecanApprovedAntibody–drug conjugateTROP2Partial signal
NCT05104866: Progression-Free Survival (On-study tumor assessments occur every 6 weeks then every 9 weeks until disease progression, death or withdrawal of consent assessed up to data cut-off (17Jul2023) to a maximum of approximately 21 months): Dato-DXd 6.9 Months (95% CI 5.7 to 7.4) vs Investigator's Choice of Chemotherapy (ICC) 4.9 Months (95% CI 4.2 to 5.5)
ElacestrantApprovedSmall moleculeEstrogen receptorPartial signal
NCT03778931: Progression-free Survival in ESR1-mut Participants (From Date of Randomization until Disease Progression or Death Due to Any Cause (up to 12 Months)): Elacestrant 3.78 months (95% CI 2.17 to 7.26) vs Standard of Care (SoC) 1.87 months (95% CI 1.87 to 2.14)
EpirubicinApprovedSmall moleculeTopoisomerase II / DNAPartial signal
NCT00309569: Overall survival (primary endpoint), preoperative vs postoperative chemo timing: HR 0.800 (95% CI 0.563-1.136), P=0.213 — no significant difference. (Secondary endpoint recurrence-free survival: HR 0.7, 95% CI 0.515-0.955, P=0.024, favoring postoperative chemo.) missed
Eribulin MesylateApprovedSmall moleculeTubulin / microtubulesPartial signal
NCT02225470: Progression-Free Survival, eribulin vs vinorelbine (independent tumor assessment): HR 0.80 (95% CI 0.65-0.98, P=0.036) in favor of eribulin; median PFS 2.8 months in both arms
NCT00337103: Co-primary endpoints, eribulin (n=554) vs capecitabine (n=548): overall survival median 15.9 vs 14.5 months, HR 0.88 (95% CI 0.77 to 1.00), P = .056; progression-free survival median 4.1 vs 4.2 months, HR 1.08 (95% CI 0.93 to 1.25), P = .30 (Kaufman et al., J Clin Oncol 2015). missed
EverolimusApprovedSmall moleculemTOR kinase, mTOR (mTORC1) (inhibitor)Partial signal
NCT02511639: Median progression-free survival: 9.9 months (everolimus + aromatase inhibitor) vs 7.2 months (aromatase inhibitor alone); HR 0.764 (95% CI 0.501-1.164)
NCT00863655: Progression-free Survival (PFS) Based on Local Radiology Review of Tumor Assessments. (date of randomization to the date of first documented tumor progression or death from any cause, whichever occurs first, reported between day of first patient randomized up to about 19 months): Everolimus + Exemestane 6.93 months (95% CI 6.44 to 8.05) vs Placebo + Exemestane 2.83 months (95% CI 2.76 to 4.14)
ExemestaneApprovedSmall moleculeAromataseReliable signal
NCT00038467: Disease-Free Survival (DFS) at Month 36 Post-Randomization: Main Study (Baseline up to Month 36): Exemestane 0.9 probability of DFS (95% CI 0.89 to 0.92) vs Tamoxifen 0.86 probability of DFS (95% CI 0.85 to 0.88)
NCT00066690: 5-year disease-free survival: 89.0% exemestane plus ovarian function suppression vs 84.7% tamoxifen alone; HR 0.68 (95% CI 0.53–0.86).
Fulvestrant (Faslodex)ApprovedSmall moleculeEstrogen receptorPartial signal
NCT01602380: Comparison of Progression-Free Survival (PFS) in Patients Treated With Fulvestrant With Those Treated With Anastrozole (Baseline RECIST 1.1 assessments (Day 0) and then every 12 weeks until the earliest of disease progression evident, patient dies or has surgery/radiotherapy for their disease (up to approximately 38 months)): Fulvestrant 500 mg 16.6 Months (95% CI 13.83 to 20.99) vs Anastrozole 1 mg 13.8 Months (95% CI 11.99 to 16.59)
NCT00099437: Progression-free survival: fulvestrant 500 mg (n=362) vs 250 mg (n=374), HR 0.80 (95% CI 0.68 to 0.94), P = .006; CT.gov median time to progression 6.5 vs 5.5 months (Di Leo et al., J Clin Oncol 2010).
Gedatolisib (Revtorpyk)ApprovedSmall moleculePI3K (class I isoforms) and mTORC1/mTORC2Partial signal
NCT05501886: VIKTORIA-1 (NCT05501886), PIK3CA wild-type cohort, primary endpoint PFS: gedatolisib+fulvestrant+palbociclib (triplet) median PFS 9.3 months vs fulvestrant alone 2.0 months, HR 0.24 (95% CI 0.17-0.35), p<0.0001; gedatolisib+fulvestrant (doublet) median PFS 7.4 months, HR 0.33 (95% CI 0.24-0.48), p<0.0001.
Imlunestrant (Inluriyo)ApprovedSmall moleculeEstrogen receptorPartial signal
NCT04975308: Investigator-assessed PFS. ESR1-mutated population: imlunestrant 5.49 vs 3.84 months with standard endocrine therapy, HR 0.617 (95% CI 0.464 to 0.821), p=0.0008. All patients: 5.55 vs 5.52 months, HR 0.867 (95% CI 0.724 to 1.039), p=0.1158 (not significant). Imlunestrant plus abemaciclib vs imlunestrant: 9.36 vs 5.49 months, HR 0.569 (95% CI 0.441 to 0.733), p<0.0001
Inavolisib (Itovebi)ApprovedSmall moleculePI3K-alphaReliable signal
NCT04191499: Progression-Free Survival (PFS) (Up to 3.7 years): Inavo+Palbo+Fulv 15 months (95% CI 11.3 to 20.5) vs Pbo+Palbo+Fulv 7.3 months (95% CI 5.6 to 9.3)
Margetuximab (Margenza)ApprovedMonoclonal antibodyHER2not yet gradedNo reviewed efficacy summary in this indication
Nab-PaclitaxelApprovedSmall moleculeMicrotubulesPartial signal
NCT00785291: Progression Free Survival (Time from randomization to progression or death due to any cause, whichever occurs first (up to 5 years)): Arm B (Nab-paclitaxel) 9.3 months (95% CI 8.15 to 10.45) vs Arm A (Paclitaxel) 10.97 months (95% CI 9.79 to 12.42) vs Arm C (Ixabepilone) 7.36 months (95% CI 6.21 to 8.18) missed
NeratinibApprovedSmall moleculeEGFR/HER2Reliable signal
NCT00878709: Invasive Disease-free Survival (iDFS) in Neratinib Arm Compared to Placebo Arm at Year 2 (From randomization until time of event up to 2 years): Neratinib 4.7 percentage of participants with events vs Placebo 7.5 percentage of participants with events
NCT01808573: Centrally Assessed Progression Free Survival (From randomization date to recurrence, progression or death, assessed up to 38 months. The result is based on primary analysis data cut.): Neratinib Plus Capecitabine 8.8 months (95% CI 7.8 to 9.8) vs Lapatinib Plus Capecitabine 6.6 months (95% CI 5.9 to 7.4)
OlaparibApprovedSmall moleculePARPPartial signal
NCT02000622: Progression-free Survival (PFS) Using Blinded Independent Central Review (BICR) According to Modified Response Evaluation Criteria In Solid Tumours (RECIST v1.1) (Radiological scans performed at baseline then every ~6 weeks up to 24 weeks, then every ~ 12 weeks thereafter until objective radiological disease progression. Assessed up to a maximum of 30 months.): Olaparib 300 mg bd 7 Months (95% CI 5.7 to 8.3) vs Chemotherapy 4.2 Months (95% CI 2.8 to 4.3)
NCT03286842: Progression-free Survival (PFS) in Real-world Setting in Germline BRCA Mutated Participants (At every visit until the earliest of disease progression, death or end of study (up to 3 years)): Olaparib gBRCAm Cohort 8.18 months (95% CI 6.97 to 9.17)
Palbociclib (Ibrance)ApprovedSmall moleculeCDK4 and CDK6Reliable signal
NCT02297438: Progression-Free Survival (PFS) Based on Investigator's Assessment: Up to Primary Completion Date (Randomization up to 65 months): Palbociclib + Letrozole 21.5 Months (95% CI 16.6 to 24.9) vs Placebo + Letrozole 13.9 Months (95% CI 13.7 to 16.6)
NCT01740427: Progression-Free Survival (PFS) as Assessed by the Investigator (From randomization date to date of first documentation of progression or death (up to approximately 2.5 years)): Palbociclib Plus Letrozole 24.8 Months vs Placebo Plus Letrozole 14.5 Months (95% CI 12.9 to 17.1)
PembrolizumabApprovedMonoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
PertuzumabApprovedMonoclonal antibodyHER2/neu Receptor AntagonistPartial signal
NCT01358877: IDFS events, pertuzumab + trastuzumab + chemotherapy vs placebo + trastuzumab + chemotherapy: 7.1% vs 8.7%, hazard ratio 0.81 (95% CI 0.66 to 1.00), p=0.0446 (log-rank); 3-year IDFS event-free rate 94.06% vs 93.24% (CT.gov posted results, data cut-off 19 December 2016).
NCT00567190: IRF-assessed progression-free survival, pertuzumab + trastuzumab + docetaxel vs placebo + trastuzumab + docetaxel: median 18.5 vs 12.4 months, hazard ratio 0.62 (95% CI 0.51 to 0.75), p<0.0001 (stratified log-rank; CT.gov posted results).
RibociclibApprovedSmall moleculeCDK4 and CDK6Reliable signal
NCT02422615: Progression Free Survival (PFS) Per Investigator Assessment (From randomization to first documented progression or death, assessed up to approximately 26 months): Ribociclib + Fulvestrant 20.5 Months (95% CI 18.5 to 23.5) vs Placebo + Fulvestrant 12.8 Months (95% CI 10.9 to 16.3)
NCT02278120: Progression Free Survival (PFS) by Investigator Assessment (From randomization to first documented progression or death, assessed up to approximately 29 months): Ribociclib + NSAI/Tamoxifen + Goserelin 23.8 Months vs Placebo + NSAI/Tamoxifen+ Goserelin 13 Months (95% CI 11 to 16.4)
Sacituzumab GovitecanApprovedAntibody–drug conjugateTROP2Partial signal
NCT03901339: Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessment (Up to 42.8 months): Sacituzumab Govitecan 5.5 months (95% CI 4.2 to 6.9) vs Treatment of Physician's Choice (TPC) 4 months (95% CI 3 to 4.4)
NCT02574455: Progression-Free Survival (PFS) by Independent Review Committee (IRC) Assessment in Brain Metastasis Negative (BM-ve) Population (From randomization until objective tumor progression or death (assessed every 6 weeks for 9 months and then every 9 weeks thereafter until the occurrence of progression of disease; maximum exposure: 29.6 months)): Sacituzumab Govitecan 5.6 months (95% CI 4.3 to 6.3) vs Treatment of Physician's Choice (TPC) 1.7 months (95% CI 1.5 to 2.6)
TalazoparibApprovedSmall moleculePARPPartial signal
NCT01945775: Progression-Free Survival (PFS): Independent Radiological Facility (IRF) Assessment (Baseline until radiologic progressive disease or death due to any cause (up to maximum duration of 36.9 months)): Talazoparib 8.6 months (95% CI 7.2 to 9.3) vs Physician's Choice Treatment 5.6 months (95% CI 4.2 to 6.7)
Tamoxifen (Soltamox)ApprovedSmall moleculeEstrogen receptornot yet graded
NCT00066690: Disease-free Survival (5-year estimates, reported at a median follow-up of 67 months.): T+OFS 86.6% (95% CI 84.2 to 88.7) | E+OFS 89% (95% CI 86.8 to 90.9) vs Tamoxifen 84.7% (95% CI 82.2 to 86.9) phase 3 result · pivotal pending
NCT00309478: At median 60-month follow-up: relapse rate 17.2% (goserelin+tamoxifen) vs 20.8% (CMF), relapse-free survival difference P=.037; local recurrence 4.7% vs 8.0%, P=.015; overall survival difference only a trend, P=.195. phase 3 result · pivotal pending
Trastuzumab DeruxtecanApprovedAntibody–drug conjugateHER2Partial signal
NCT04494425: Progression-Free Survival (PFS) Assessed by Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Low Population (Response evaluations performed at screening, every 6 weeks (q6w) ± 1 week from randomization for 48 weeks, and then every 9 weeks (q9w) ± 1 week, starting at Week 48 until PD, up to PCD of 18 March 2024 (maximum of approximately 43.85 months)): T-DXd 13.2 months (95% CI 11.4 to 15.2) | Chemotherapy 8.1 months (95% CI 7 to 9)
NCT03734029: Progression-free Survival (PFS) Based on Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer (From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years): Trastuzumab Deruxtecan (T-DXd) 10.1 months (95% CI 9.5 to 11.5) | Physician's Choice 5.4 months (95% CI 4.4 to 7.1)
Trastuzumab EmtansineApprovedAntibody–drug conjugateHER2 (ERBB2)Partial signalFeatured results are non-efficacy only in this race
TucatinibApprovedSmall moleculeHER2Reliable signal
NCT05132582: HER2CLIMB-05 (NCT05132582), primary endpoint PFS: median 24.9 months with tucatinib vs 16.3 months with placebo; HR 0.641 (95% CI 0.514-0.799); P<.0001.
NCT03975647: Progression-Free Survival (PFS) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v)1.1 Based on Investigator Assessment (From the date of randomization to the date of PD or death from any cause or censoring date, whichever occurred first (maximum up to 43 months)): Tucatinib+ Ado-trastuzumab Emtansine 9.5 Months (95% CI 7.4 to 10.9) vs Placebo+ Ado-trastuzumab Emtansine 7.4 Months (95% CI 5.6 to 8.1)
Vepdegestrant (Veppanu)ApprovedSmall moleculeEstrogen receptorPartial signal
NCT05654623: PFS by BICR vs fulvestrant: ESR1-mutation population median 5.0 vs 2.1 months, hazard ratio 0.58 (95% CI 0.43 to 0.78), P<0.001; all randomized patients 3.8 vs 3.6 months, hazard ratio 0.83 (95% CI 0.69 to 1.01), P=0.07 (NEJM 2025).
NCT04072952: Clinical benefit rate 38% (total n=71), the trial's primary endpoint (VERITAC expansion); CBR 51.2% in ESR1-mutant patients (n=41)
BEBT-209Phase 3Small moleculeCDK4 (selective)not yet gradedNo reviewed efficacy summary in this indication
CPO301Phase 3Antibody–drug conjugateEGFRnot yet gradedNo reviewed efficacy summary in this indication
Docetaxel (HB1801)
Phase 3(overall)
Small moleculeMicrotubules (tubulin)
not yet graded(overall)
No reviewed efficacy summary in this indication
Patritumab DeruxtecanPhase 3Antibody–drug conjugateHER3Weak signalNo reviewed efficacy summary in this indication
Sacituzumab TirumotecanPhase 3Antibody–drug conjugateTROP2Partial signal
NCT05347134: OptiTROP-Breast01 (NCT05347134), primary endpoint median PFS: sac-TMT 6.7 months vs chemotherapy 2.5 months; HR 0.32 (95% CI 0.24-0.44); p<0.00001
Trastuzumab RezetecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
(Z)-EndoxifenPhase 2Small moleculeEstrogen receptor (antagonist)Partial signal
NCT03931928: Primary endpoint (proportion of patients with steady-state (Z)-endoxifen plasma concentration >32 nmol/L after 6 weeks): higher proportion achieved target in both (Z)-endoxifen supplementation arms (3mg and 1.5mg) than in the control/placebo arm, P<0.0001.
JS207Phase 2Multispecific antibodyPD-1 + VEGFAnot yet gradedNo reviewed efficacy summary in this indication
TersolisibPhase 2Small moleculePI3K-alpha (mutant-selective, allosteric)not yet gradedNo reviewed efficacy summary in this indication
ECI830Phase 1/2Small moleculeCDK2not yet gradedNo reviewed efficacy summary in this indication
GVV858Phase 1/2—CDK2not yet gradedNo reviewed efficacy summary in this indication
HRS-2189Phase 1/2UndisclosedKAT6A / KAT6Bnot yet gradedNo reviewed efficacy summary in this indication
HRS-6208Phase 1/2UndisclosedCDK7not yet gradedNo reviewed efficacy summary in this indication
TegtociclibPhase 1/2Small moleculeCDK2not yet gradedNo reviewed efficacy summary in this indication
IEV407Phase 1——not yet gradedNo reviewed efficacy summary in this indication
JNJ-101684362Phase 1Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
RAE346
—(overall)
Small moleculePI3Kα (mutant-selective)not yet gradedNo reviewed efficacy summary in this indication
Sabizabulin
Discontinued
Small moleculeMicrotubules (tubulin)
not yet graded(overall)
No reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Ixabepilone to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 2Breast CancerActive not recruiting
Est. primary completion 2026-12-31 · NCT00877500 · CT.gov ↗
What to watch

See the full readout calendar ↗